How We’re Helping Battle a Global Epidemic: Non Communicable Diseases (NCDs)

Over the past year, we have made multiple in-roads into providing support for healthier communities across the globe. Our new report, 2017 Social Impact Report highlights our commitment to corporate responsibility and transparency and demonstrates the ways our business uniquely supports this belief.

How We’re Helping Battle a Global Epidemic: Non Communicable Diseases (NCDs)

Looking at what we’ve done to address the challenges of non-communicable diseases (NCDs) in 2017 is telling as a microcosm of how we’re working to be true to our mission of helping people live better days.

Around the world, NCDs are an ever-growing threat—and the burden of dealing with them falls disproportionately on low-income countries. The prevention and management of NCDs is a global priority—in fact, the United Nations 2030 Agenda for Sustainable Development targets reducing premature deaths from NCDs by one-third.

We join forces with government and industry peers wherever possible to improve access to essential medicines to treat chronic conditions. For example, in 2017, Teva joined an international coalition that is working together to increase access for essential medicines and products to prevent and treat NCDs.

Through our conversations with health experts, we identified people who suffer from two or more conditions as an emerging health challenge directly related to NCDs. In 2017, our research report, Multiple Chronic Conditions: The Global State, quantified the burden of MCC on patients, communities and health systems. That same month, we provided $300,000 to four clinics across the United States to support patients with MCC via a two-year Enhancing Access2Care grant program with Direct Relief and Volunteers in Medicine.

We continued raising awareness around the importance of addressing this public health challenge by hosting more than 40 experts with the International Association of Patient Organizations at the World Health Assembly in Geneva with a goal of aligning policy agendas to support people with MCC. We also assembled leaders in global health to discuss potential solutions at the World Economic Forum (WEF) Sustainable Development Impact Summit.

Teva also launched a partnership with Mount Sinai’s Arnhold Institute for Global Health in New York to design and evaluate a patient-centered, integrated approach for people with MCC. The insights developed from our collaboration have brought this important health issue to the forefront and have since been cited in numerous esteemed scientific publications.

Teva’s focus on NCDs has yielded real benefits for people around the world who otherwise may not have had access to medicines and services that enable them to live better days.